I think the FDA priority review is a milestone, but still the ultimate decider is the approval in 6 month.
however, given the valuation, I think the market could overlook the positive validation from priority review. Because it could potentially mean other MSB products can achieve similar special status, affirming their life saving advantages
I think the FDA priority review is a milestone, but still the...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
-0.050(4.67%) |
Mkt cap ! $1.161B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | $1.01 | $3.119M | 3.035M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 211647 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 19094 | 9 |
View Market Depth
| Last trade - 11.32am 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |